Barbero Allende J M, Ureña I, Cañivano L, García S, Paz C, Olmo-Ruiloba A, Jauregi K, Coronado S, López Requejo L, Porcel L, Perea V, Irigoyen M, Cano J, García A, León E, Fernández-Domingo N, Lanchares P, Lino B, Ortolá M, Lizasoain A, Sánchez V, Arévalo-Cañas C, Arévalo-Serrano J
José Mª Barbero Allende. Servicio de Medicina Interna. Hospital Universitario Príncipe de Asturias. Alcalá de Henares (Spain).
Rev Esp Quimioter. 2025 Feb;38(1):48-54. doi: 10.37201/req/086.2024. Epub 2024 Nov 26.
One of the main problems with Clostridioides difficile infection (CDI) is its tendency to recur. The objective of the study is to analyze which factors in the clinical management of CDI favor recurrence.
This is a retrospective study conducted at the Hospital Universitario Príncipe de Asturias on cases of CDI between January 2021 and June 2023. Demographic variables, comorbidities, risk factors for recurrence, and treatments used for CDI were recorded. Non-optimal clinical management was defined as: not discontinuing treatment with proton pump inhibitors (PPIs) if the patient was on them, not discontinuing concomitant antibiotic treatments if the patient was on these, the use of metronidazole monotherapy in any case, or the use of standard-dose vancomycin if there were risk factors for recurrence.
A total of 327 cases were found in 256 patients. 69 patients died within 8 weeks after the episode (26.9%). Among the remaining 258 episodes, there were 68 recurrences (26.3%). Of these 68 recurrences, 63 cases received nonoptimal treatment (93.2%), compared to 112/190 (58.9%) among those who did not recur. In the multivariate analysis adjusted for confounding factors, patients who received optimal treatment had an 89% lower risk of recurrence compared to those who did not receive it (OR 0.1; p < 0.001).
Reducing the use of PPIs and antibiotics and prioritizing more effective treatments against CDI could improve the recurrence rates of this infection.
艰难梭菌感染(CDI)的主要问题之一是其复发倾向。本研究的目的是分析CDI临床管理中的哪些因素有利于复发。
这是一项在阿斯图里亚斯王子大学医院进行的回顾性研究,研究对象为2021年1月至2023年6月期间的CDI病例。记录了人口统计学变量、合并症、复发风险因素以及用于CDI的治疗方法。非最佳临床管理定义为:如果患者正在使用质子泵抑制剂(PPI),则不停止使用;如果患者正在使用抗生素,则不停止联合使用抗生素;在任何情况下使用甲硝唑单药治疗;或者在存在复发风险因素时使用标准剂量万古霉素。
共在256例患者中发现327例病例。69例患者在发病后8周内死亡(26.9%)。在其余258次发病中,有68例复发(26.3%)。在这68例复发中,63例接受了非最佳治疗(93.2%),而未复发的患者中这一比例为112/190(58.9%)。在对混杂因素进行调整的多变量分析中,接受最佳治疗的患者与未接受最佳治疗的患者相比,复发风险降低了89%(比值比0.1;p<0.001)。
减少PPI和抗生素的使用,并优先采用更有效的CDI治疗方法,可能会提高这种感染的复发率。